MedTrace Logo

Ultrasound-Guided Intermediate Cervical Plexus Block for Postoperative Analgesia in Vagus Nerve Stimulation Surgery

NCT07689617 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2026-07-08

No results posted yet for this study

Summary

This prospective, randomized, double-blind, placebo-controlled clinical trial aims to evaluate the analgesic efficacy of ultrasound-guided intermediate cervical plexus block (ICB) in patients undergoing vagus nerve stimulation (VNS) implantation surgery under general anesthesia. Participants are randomly assigned to receive either an ultrasound-guided ICB with 10 mL of 0.25% bupivacaine or a placebo injection with 10 mL of normal saline following induction of general anesthesia. The primary outcome is total postoperative morphine consumption during the first 24 hours after surgery. Secondary outcomes include intraoperative remifentanil consumption, postoperative pain intensity assessed using the Numeric Rating Scale (NRS), time to first analgesic request, length of hospital stay, and postoperative seizure incidence.

Conditions

  • Drug-Resistant Epilepsy
  • Epilepsy
  • Vagus Nerve Stimulation

Interventions

PROCEDURE

Ultrasound-guided intermediate cervical plexus block

Ultrasound-guided intermediate cervical plexus block performed after induction of general anesthesia.

DRUG

Sodium Chloride 0.9% in 10 ml injection

10 mL of 0.9% sodium chloride administered as a placebo injection under ultrasound guidance.

DRUG

Bupivacaine

10 mL of 0.25% bupivacaine administered during ultrasound-guided intermediate cervical plexus block.

Sponsors & Collaborators

  • Firat University

    lead OTHER

Principal Investigators

  • Ahmet Aksu, Assistant Professor · Fırat University Faculty of Medicine Department of Anaesthesiology and Reanimation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2023-05-01
Completion
2023-05-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07689617 on ClinicalTrials.gov